In conclusion, our study suggests that although HER2-low breast cancer should not be regarded as a separate molecular entity, the presence of ctDNA in MBC patients indicates that HER2-low MBC may possess certain unique characteristics. The gene discussed is ERBB2; the disease is breast carcinoma.